Crispr Earnings: Blockbuster Potential for Casgevy; Shares Undervalued for Long-Term Investors

Crispr Therapeutics has achieved many recent milestones, most notably the approval of Casgevy for the treatment of patients with either sickle cell disease or transfusion-dependent beta thalassemia. Additionally, clinical trials are advancing for its early-stage pipeline with candidates evaluating the treatment of Type 1 Diabetes, liquid and solid tumors, and cardiovascular diseases. We maintain our positive long-term outlook and fair value estimate of $119 per share. We view the stock as undervalued, currently trading in 4-star territory about 30% below our fair value estimate. Crispr provides long-term investors who possess a high degree of risk tolerance with pure-play exposure to novel gene editing technology.